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ABSTRACT 
Miniaturised solvent casting (MSC) has been developed as a method for screening the stability 
of amorphous solid dispersions (ASD) of BCS class II drugs. The aim of the work was to further 
develop a rapid screening technique for drug-polymer amorphous dispersions made by solvent 
removal techniques. A second aim was to assess the impact of varying dissolution solvent on the 
resultant ASD stability. The technique was rapid, repeatable and practically straightforward. 
Storage stability of resultant ASD films was monitored over 4 weeks. The method is suited to pre-
formulation as a risk-reduction tool during the formulation of drug product. Four drugs, seven 
polymers and five solvents have been examined. The resultant ASD films were monitored for 
stability and homogeneity over a four week period using polarised light microscopy (PLM), X-ray 
powder diffraction (XRD) and photography. A qualitative scoring system indicating the 
approximate proportion of amorphous and crystalline content of the films was developed. Results 
were rationalised against the physiochemical properties of the drugs, the functionality of the 
polymeric excipients and the physical properties of the solvents. 
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1. INTRODUCTION 
Combinatorial chemistry and robotics have left a challenging legacy to the drug product 
formulation scientist. Up to 70% of new chemical entities (NCE) and 40% of marketed drugs are 
poorly soluble in water.1 A number of strategies such as salt-formation, co-crystals, particle size 
reduction, micro emulsions, etc. have been successfully deployed to counteract low in vivo 
solubility.2 In selected cases, amorphous solid dispersions (ASD) have been found to be excellent 
solutions. However, despite decades of research in the area and the pioneering work of Zografi3 and 
co-workers,4 relatively few examples of commercialised ASD pharmaceuticals exist.5 This is at 
least partly attributable to the reputation of such systems towards spontaneous crystallisation, but 
also due to the perception that crystalline drug products are less risky.6 Nevertheless, ASD offer 
order-of-magnitude better solubility than their pure crystalline counterparts and remain a highly 
active area of research. 
When generating amorphous solid dispersions of drugs, polymeric excipients have often been 
used to stabilise the systems.7 Due to their high molecular weight and high entropy, polymers often 
resist the ordered stacking required for spontaneous crystallisation. They can form a matrix around 
a substance, hence reducing the likelihood of molecular motion. Physical properties of the polymer 
like glass transition temperature (Tg) are a function of molecular weight. Polymers are more likely 
to be glassy solids than the active pharmaceutical ingredient (API) and dispersions of the drug-
polymer are also more likely to be glassy. The miscibility of the drug-polymer ASD is a key factor8 
in maintaining stable dispersions. Intermolecular forces such as hydrogen bonding are critical in 
maintaining a homogenous phase. Reliable methods for predicting the stability of drug-polymer 
dispersions are of great value. 
 
Fig 1: Drugs involved in the study and their selected physical properties: molecular weight (MW), melting point (MP), 
glass transition temperature (Tg), number of hydrogen bond acceptors (HAc) and donors (HD). 
DSC has generally been considered the gold-standard technique for assessing the stability of 
amorphous dispersions. Predictive aids like In Silico modelling,1 data mining,8 high throughput 
screening9 and design of experiments have been powerful approaches in the quest to reduce risk and 
define a robust design space for amorphous dispersions. The beneficial effect of polymers on the 
stability of supersaturation, granulation and storage have all been investigated.10 A wide range of 
analytical techniques such as FTIR, XRD, PLM, ssNMR, DSC, AFM, Raman and many others 
have been utilised to monitor stability of the dispersions over time. 
In this work, we have focused on expanding upon a miniaturised solvent casting (MSC) method 
as a predictive tool for ASD stability. In particular, the ability of the technique to screen BCS class 
II drugs and also chemically diverse GRAS polymers was investigated. Similar techniques have 
previously been used, but are often focused on one specific model system, or detailed spectroscopic 
analysis of same. We herein assess the method itself and look at four drugs, seven polymers and 
five solvent systems. We have also considered the effect of the dissolution solvent on the stability 
of the resultant solid. To the best of our knowledge, the effect of a 'legacy' solvent on the stability of 
ASD has not been previously investigated. 
Rather than identifying a 'design space' for formulation, we focused only on developing solvent 
casting as a screening technique. The practical simplicity of the technique is part of the inherent 
advantage. It does not rely on the significant time or expense required for in silico software 
programming, data mining licences nor capital expenditure. It can be seen as a pre-formulation tool 
for the solvent removal synthesis of ASD. 
MSC can aid decision-making with polymer selection, solvent selection and be used to 
investigate the potential stability of novel amorphous drug-drug combinations. Furthermore it is a 
realistic screening technique, as it involves the physical removal of a selected solvent from a given 
drug-polymer combination. Real-world solutions help to circumnavigate potential pitfalls or subtle 
interactions which can be omitted in computed models. Such unforeseen omissions can be 
extremely costly in the formulation development of highly valuable NCE. The authors therefore 
strongly recommend the use of MSC in series with simulation research. 
The downside to the technique is the rather repetitive practical work: involving accurate 
weighing, accurate pipetting and most importantly, meticulous record keeping. In our case, it was 
found that Excel worksheets were a good way of managing the volume of data. Handling 
amorphous films during stability trials and carrying out the analytical work without contaminating 
the samples was challenging. Any careful and competent scientists could complete the tasks, but the 
risk of handling or data errors is significant, particularly with less experienced operators. 
Automation is a potential solution, particularly for the synthesis steps, but perhaps also for the 
analysis. 
The objectives of this study are to expand and improve upon existing methods for miniaturised 
solvent casting (MSC) of ASD. Within the sphere of consideration are BCS class II drugs, GRAS 
excipient polymers and a variety of low toxicity solvents. The effects of the physical properties of 
the drug (e.g. Tg) and its quotient of hydrogen bonding acceptor and donors are of interest. The type 
and substitution patterns of polymers are relevant. The effect of the solvent system used is 
interesting. The work can be described in three different parts: (a) the effect of drug physiochemical 
properties, (b) the effect of polymer properties and (c) the effect of solvent choice in the resultant 
ASD. We are casting the net wide, to look for patterns in successful and unsuccessful ASD. The 
nature of these patterns will funnel our future work direction and may provide further insight into 
these elusive structures. 
2. MATERIALS AND METHODS 
2.1 Materials 
Solvents were purchased from Sigma-Aldrich, Fluka and Fisher and were >99% purity in all 
cases. Polymers Kollidon 25, Kollidon 30, Kollidon VA 64, Kollidon SR and Soluplus were 
donated by BASF. Polymers AQOAT AS-HG (HPMC-AS), HPMCP HP-55 (HPMC-P) and 
Metolose 90SH-4000 (HPMC) were donated by Shin Etsu. Drugs indomethacin and fenofibrate and 
polymer PVP 10 were purchased from Sigma-Aldrich. Felodipine was purchased from King Stone 
and acetaminophen was donated by GSK. 
2.2 Preparation of Amorphous Solid Dispersions: 
In a typical experiment, felodipine (50 mg) and Soluplus (50 mg) were weighed into a sample 
vial and dissolved in acetone-methanol (30:7, 4.0 ml) by vortex spinning at room temperature. The 
appearance of the solution was noted (i.e. clear, hazy, suspension or insoluble). A microscope slide 
(1 mm thick) was cut to size (for XRD mounting), labelled and heated on a hotplate (T = 60 oC). A 
small volume of the solution (60 µl) was pipetted dropwise onto the heated slide and the solvent 
was removed over 2 minutes. The slide was stored at ambient temperature (18-24 oC) and RH (25-
35%) for 4 weeks. 
An ASD of felodipine-Soluplus was synthesised by weighing felodipine (5.0g) and soluplus 
(5.0g) into a round-bottomed flask and dissolving in acetone-methanol (30:7, 100ml) then 
evaporating to dryness by rotary evaporation. The solid was further dried on a high-vacuum line (4 
x 10-3 mBar) for 2 hours to give a yellow-white foam (9.90g, 99%). 
2.3 ASD Analysis 
Non-invasive techniques PLM and XRD were used. Analysis was typically performed at Day 0, 
Week 1 and Week 4.time points In general, there was excellent qualitative agreement between the 
techniques used. 
2.3.1 Polarised Light Microscopy 
A Zeiss Imager A1m microscope, equipped with an AxioCam MRc 5 camera, linked to a 
computer running AxioVision software (release 4.7) was used for polarised light microscopy 
(PLM). All micrographs were taken at x50 magnification. 
2.3.2 X-ray diffraction 
A PANalytical Empyrean X-ray diffractometer attached to a computer running High Score Plus 
was used to collect and process X-ray data. Diffraction patterns were collected in-situ, by spinning 
the glass slide samples within the X-ray beam. Plasticine™ was used to mount the slide in the 
holder at the correct height. The radiation was generated by Cu filter at 40 kV and 40 mA. Data was 
collected over the 2θ range of 5-50o, with a step size of 0.026o and a step time of 56 s. 
2.3.3 Solid state nuclear magnetic resonance spectroscopy 
13C solid state NMR spectra were recorded on a Bruker Avance III instrument operating at a 
carbon frequency of 125.8 MHz. Samples were spun at the magic angle (54.7o) at a frequency of 
37.5 kHz at temperature 295 K. The spectra were obtained using the cross polarisation magic angle-
spinning (CP/MAS) method. The contact time was 3 ms and the pulse delay between scans was 5 s. 
3. RESULTS AND DISCUSSION 
MSC is compatible with a wide variety of analytical techniques. Herein we focused on PLM and 
XRD along with photographic records of films on glass slides. These techniques are non-invasive, 
i.e. they require no physical or chemical manipulation of the sample prior to analysis. This was 
important as invasive techniques can potentially disturb or damage the molecular structure of the 
samples. During a stability study this is particularly important. The attraction of PLM and XRD is 
that only electromagnetic radiation passes through the samples. DSC is an informative technique, 
but in these experiments it would have required the removal of an aliquot of sample to place in a 
DSC pan. The passage of heat through the sample would also disrupt the structure. Nevertheless, 
DSC is a widely-employed technique and will be utilised in ongoing work in tandem with these 
analyses. 
Here we have focused on PLM as a clear and concise method for visualising a sample. 
Birefringence is very clear in thin films when crystals are present. X-ray diffractograms can be 
recorded directly by mounting the glass slides at the surface of a holder using Plasticine™ or other 
such mouldable amorphous materials. Bragg peaks were very clear (even with low quantities of 
crystals) and gave information which could potentially be quantitated or used to identify 
polymorphs. A matching of Bragg peaks with (for example) the Cambridge structural database or 
the quantitation of crystalline fraction of the films by relating to the intensity of the peaks is 
possible and could be investigated in future work. When no crystals were present, only an 
amorphous 'halo' was recorded. Blank slides or Plasticine™ only also gave the 'halo' result. As both 
techniques are sensitive and non-invasive, they are very well suited to monitoring the qualitative 
structure of the samples. 
In this work, four drugs, seven polymers and five solvents were studied. The effects of the drug, 
the polymer and the solvent on stability have been considered. The physical properties of the drugs 
in Figure X will affect their solubility. Generally, higher molecular weights will tend to have higher 
melting points and higher glass transition temperatures. However the functionalisation (number and 
nature of functional groups) of the molecule will have a significant impact on its melting point, in 
particular hydrogen bonding functional groups. Felodipine and indomethacin both have hydrogen 
acceptor (HAC) and hydrogen donor (HD) groups. In contrast, fenofibrate has no hydrogen donor. 
Intermolecular hydrogen bonding is therefore not possible for pure felodipine and this is illustrated 
in the low melting point (80 oC) and very low glass transition temperature (-16 oC). 
Experiment 
Analysis 
Timepoint Day 0 Week 1 Week 4 
Pure felodipine, no 
polymer, 
acetone-methanol 
solvent 
PLM 
   
XRD 
   
Rating AAAA AAAA AACC 
Felodipine, Soluplus, 
acetone-methanol 
solvent 
PLM 
   
XRD 
   
Rating AAAA AAAA AAAA 
Pure fenofibrate, no 
polymer, acetone-
methanol solvent 
PLM 
   
XRD 
   
Rating AAAA ACCC ACCC 
No drug, Kollidon K25 
polymer, acetone-
methanol solvent 
PLM 
   
XRD 
   
Rating AAAA AAAA AAAA 
Table 1, Polarised light microscopy (PLM) and X-ray diffraction (XRD) data of some selected ASD during the 4 week 
stability trial. PLM and XRD were taken at time points day 0, week 1 and week 4. The ratings qualitative in nature and 
indicate fully amorphous (AAAA), mostly amorphous (AAAC), half-and-half (AACC), mostly crystalline (ACCC) and 
completely crystalline (CCCC) films of material. 
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Solvent Acetone Methanol Acetonitril
e 
Ethanol Water 
ICH (ppm) Class 3 3000 410 N/A N/A 
B.P. (oC) 56.3 64.7 81.6 78.3 100 
ΔHV (kJmol-1) 
29.1 35.3 33.8 38.7 40.7 
ε 
20.7 32.6 37.5 24.3 78.5 
KTα 0.08 0.98 3.44 0.86 1.17 
KTβ 0.43 0.66 - 0.75 0.47 
Table 2: Selected physical properties of the 'legacy' solvents used in the solvent casting study. Properties considered 
most relevant to evaporation, solvation and hydrogen bonding have been included.
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This belies the fact that fenofibrate has a comparable molecular weight (361 gmol-1) to felodipine 
(384 gmol-1) and indomethacin (358 gmol-1), but the melting points of the three drugs vary 
considerably (80, 145 and 151 oC respectively). Felodipine and indomethacin both have one HD 
each, and similar numbers of HAC (3 and 4 respectively). However, felodipine contains a primary 
amine and two ester groups, whereas indomethacin has a tertiary amine, an ether and a free 
carboxylate. Therefore the interactions of the two API with the same polymeric excipient will 
differ. Acetaminophen has different physical properties: it is BCS class III, with a far higher 
solubility in water (1.4 x 104 mg.ml-1). The melting point is 170 oC and glass transition is 22.6 oC. 
Acetaminophen has two H-bond acceptors and two H-bond donors, making it a different example to 
the other drugs, but interesting due to the hydrogen bonding possibilities. Acetaminophen was also 
a faster crystalliser that the other three drugs. 
Polymers were chosen based on GRAS status and structural features. In particular, vinyl-derived, 
cellulose-derived and specialist polymers were investigated. The povidones are vinyl derivatives 
showing excellent general solubility and stability. They are known to be very hygroscopic and 
different grades will vary in average molecular weight, viscosity, glass transition temperature and 
bulk density. The examples chosen in this study were PVP 10, K25 and K30. Also included were 
Kollidon VA64, which is a copovidone containing amide and acetate functional groups in a 6:4 
ratio and Kollidon SR: a spray-dried polyvinyl acetate-containing povidone. The specialised 
polymer Soluplus was designed to withstand the heat of hot melt extrusion and also to form stable 
homogenous dispersions. It contains amide, acetate and ether functional groups and can also be 
formulated by the solvent method. In contrast to these synthetic polymers, cellulose derivatives are 
formed from a natural product. HPMC contains polyol, methyl ether and hydroxyisopropyl ether 
functionality, along the cellulose backbone. HPMCAS contains the previous functional groups, but 
also includes acetate and succinate derivatives. HPMCP is similar to HPMC, but with phthalate 
esters. Already the variety of functionalisation and the difference in backbone flexibility will have a 
significant impact on the nature of the dispersions. Polymer polarity, flexibility and the ability to 
donate and accept hydrogen bonds will be of critical importance. 
Solvents chosen were acetone-methanol mixture, acetonitrile mixture, acetonitrile, ethanol and 
ethanol-water mixture. Only solvents with superior ICH limits were included, therefore chloroform 
and dichloromethane were not considered on this occasion. Mixtures were utilised in order to 
broaden the likelihood of solubility of a certain combination. The solvation requirements of the 
system, in particular polymers, will differ. Favour was given to solvents with low boiling points and 
favourable ICH limits (e.g. acetone b.p. 56.3 oC ICH class 3). The solvent mixture of acetone-
methanol (30:7) was carefully chosen, firstly because of the ability to solubilise a wide range of 
chemically diverse species, but also because it forms an azeotropes at mole fraction 0.75% acetone, 
that boils at 54.5-55.5 oC. Such azeotropes represent cost reductions should such processes be 
scaled-up. Furthermore, both acetone and methanol are inexpensive and low in toxicity. 
A second goal of the work was to investigate the effect of legacy solvents on the stability of 
ASD made by solvent-casting. Consider ASD DxPyA, made from a drug X and polymer Y 
dissolved in solvent A., Will DxPyA have the same stability as ASD DxPyB made by casting of 
drug X and polymer Y from a solution in solvent B? It might be assumed that DxPyA and DxPyB 
are identical and will therefore behave identically on stability. However, it is very possible that 
differences in the physiochemical properties of the solvent will impact on the stability of the 
resultant ASD. 
Formulation Day 0 Wk 1  Wk 4 Formulation Day 0 Wk 1 Wk 4 
Pure felodipine AAAA AAAA AACC Fenofibrate-HPMCP AAAA AACC AACC 
Felodipine-
PVP10 
AAAA AAAA AAAA Pure indomethacin AAAA AAAC AAAC 
Felodipine-K25 AAAA AAAA AAAA Indomethacin-
PVP10 
AAAA AAAA AAAA 
Felodipine-K30 AAAA AAAA AAAA Indomethacin-K25 AAAA AAAA AAAA 
Felodipine-
Soluplus 
AAAA AAAA AAAA Indomethacin-K30 AAAA AAAA AAAA 
Felodipine-VA64 AAAA AAAA AAAA Indomethacin-
Soluplus 
AAAA AAAA AAAA 
Felodipine-KSR AAAA AAAA AAAA Indomethacin-VA64 AAAA AAAA AAAA 
Felodipine-
HPMCAS 
Not soluble Indomethacin-KSR AAAA AAAA AAAA 
Felodipine-
HPMCP 
AAAA AAAA AAAA Indomethacin-
HPMCAS 
Not soluble 
Pure fenofibrate AAAA ACCC ACCC Indomethacin-
HPMCP 
AAAA AAAA AAAA 
Fenofibrate-
PVP10 
AAAA CCCC CCCC Pure acetaminophen ACCC CCCC CCCC 
Fenofibrate-K25 Not soluble Acetaminophen- AAAA - AAAA 
PVP10 
Fenofibrate-K30 Not soluble Acetaminophen-K25 AAAA - AAAA 
Fenofibrate-
Soluplus 
AAAA AAAA AAAC Acetaminophen-K30 AAAA - AAAA 
Fenofibrate-
VA64 
AAAA ACCC CCCC Acetaminophen-
Soluplus 
AAAA - AAAA 
Fenofibrate-KSR AAAA AAAA AACC Acetaminophen-
VA64 
AAAA - AAAA 
Fenofibrate-
HPMCAS 
Not soluble Acetaminophen-KSR AAAC - AACC 
Table 3, Drug-Polymer ASD stability results at Day 0, week 1 and week 4 (All films made from acetone:methanol 
(30:7) solvent). K25 is Kollidon 25, VA64 is Kollidon VA64, KSR is Kollidon SR. The ratings qualitative in nature and 
indicate fully amorphous (AAAA), mostly amorphous (AAAC), half-and-half (AACC), mostly crystalline (ACCC) and 
completely crystalline (CCCC) films of material. Ratings shown are the mean of XRD and PLM values. 
N
H
CH3CH3
Cl
Cl O
O
CH3
O
O
CH3
Felodipine
N
O
CH3
O
OH
O
O
CH3
O
O
OH
Soluplus
1
2
2a
3
3a
3b
3c
4
5
6
6a
5a
5b 1'
2'
3'
4'
5'
6'
x
z
y
a
b
c
d
e
f
g
h
i
j
k
l
m
no
p q
r
s
t
u
 
δC Felodipine: 15.05 (3c); 
18.98 (6a); 20.40 (2a); 38.33 
(4); 50.36 (5b); 58.83 (3b); 
103.78 (5); 104.88 (3); 127.89 
(5', 4'); 129.40 (2'); 133.0 (6', 
3'); 146.03 (2); 147.33 (6); 
151.12 (1'); 166.61 (3a); 
168.69 (5a). 
 
δC Soluplus: 21.51 
(c); 23.00 (r); 30.84 
(e, d); 37.74 (b, i, k); 
42.86 (f); 46.33 (h); 
67.93, 71.18 (j, l, m, 
n, o, p, s, t, u); 170.31 
(q); 175.51 (a). 
 
δC Felodipine-Soluplus ASD: 14.73 (fel 
3c); 18.91 (fel 6a); 21.08 (Sol c, fel 2a); 
23.20 (Sol r); 30.38 (Sol e, d); 38.16 (fel 
4, Sol b, i, k); 42.83 (Sol f); 46.49 (Sol h); 
50.80 (fel 5b); 59.71 (fel 3b); 68.45, 70.95 
(Sol j, l, m, n, o, p, s, t, u); 103.60 (fel 5, 
3); 129.08 (fel 5', 4', 2'); 133.00 (fel 6', 3'); 
146.66 (fel 2, 6, 1'); 167.50 (fel 3a, 5a); 
170.11 (Sol q); 176.56 (Sol a). 
Figure 2, Numbering system for felodipine and for Soluplus. Assignment of 13-C NMR spectra 
 Figure 3, The 13-C solid-state NMR spectra of  (A) crystalline felodipine, (B) amorphous Soluplus and (C) an 
amorphous solid dispersion of felodipine-Soluplus. The data compared well with that previously reported.
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Felodipine was solvent casted as the pure drug and in combination with seven polymers from 
acetone-methanol mixture. The pure drug crystallised between weeks one and four. All polymeric 
systems stabilised felodipine for the full four weeks of the test. The stability of these systems could 
be partly attributable to the favourable molecular weight (384 gmol-1), Tg (40 oC) and number of 
hydrogen accepting groups (3) and donating groups (1) in felodipine. The miscibility with polymers 
PVP10, K25, K30, VA64, KSR, Soluplus and HPMCP may be favourable. 
Indomethacin was solvent casted as the pure drug and in combination with seven polymers from 
acetone-methanol mixture. The pure drug crystallised between day 0 and week 1. All polymeric 
systems stabilised felodipine for the full four weeks of the test. The stability of these systems could 
be partly attributable to the favourable molecular weight (357 gmol-1), Tg (41 oC) and number of 
hydrogen accepting groups (4) and donating groups (1) in indomethacin. The miscibility with 
polymers PVP10, K25, K30, VA64, KSR, Soluplus and HPMCP appeared favourable. 
Acetaminophen was solvent casted as the pure drug and in combination with six polymers from 
acetone-methanol mixture. The pure drug crystallised between on day 0. Five of the drug-polymer 
ASD remained stable over the 4 week test. Kollidon SR crystallised on day 0. The reason for this 
result is not understood. The molecular weight (151 gmol-1), Tg (23 oC) and number of hydrogen 
accepting groups (2) and donating groups (2) in acetaminophen will influence the system stability. 
The miscibility with polymers PVP10, K25, K30, VA64, and Soluplus appeared favourable. 
Fenofibrate was solvent casted as the pure drug and in combination with seven polymers from 
acetone-methanol mixture. The pure drug crystallised between week 1 and week 4. Three of the 
drug-polymer dispersions crystallised between day 0 and week 1: PVP10, VA64 and HPMCP. Two 
dispersions crystallised between week 1 and week 4: KSR and Soluplus. Surprisingly, fenofibrate 
did not dissolve in the acetone-methanol mixture when combined with K25 or K30, but did dissolve 
PVP10. This result is not completely understood, but may be due to the viscosity or molecular 
weight difference between the PVP10 and the higher molecular weight povidone solutions. The 
stability of fenofibrate dispersions is influenced by the molecule's molecular weight (361 gmol-1), 
Tg (-16 oC) and number of hydrogen accepting groups (3) and donating groups (0). In particular the 
lack of any hydrogen bond donors makes this molecule very difficult to stabilise by amorphous 
solid dispersion. The absence of intermolecular H-bonds in the pure drug is also a contributing 
factor to the low glass transition temperature. 
Acetaminophen was solvent casted from five 'legacy' solvents: acetone-methanol mixture, 
acetonitrile-methanol mixture, pure acetonitrile, pure ethanol and ethanol-water mixtures. 
Acetaminophen was solvent casted in six ASD with different polymers from acetone-methanol 
mixture. Five of these ASD remained fully amorphous for the full 4 week test: PVP10, K25, K30, 
VA64 and Soluplus. The exception was acetaminophen-KSR which crystallised on day 0. This is 
probably due to a weaker interaction between KSR and acetaminophen than with the other 
polymers. 
Acetaminophen was also solvent casted into seven ASD by combination with polymers from 
acetonitrile-methanol. Only three of these ASD remained stable over the four week test: the 
povidones PVP10, K25 and K30. Two of the systems crystallised on day 0: KSR and HPMCP. Two 
polymers, VA64 and Soluplus, crystallised between day 0 and week 4. 
Acetaminophen was solvent casted into seven ASD by combination with polymers from pure 
acetonitrile. Two ASD remained stable for the four weeks: PVP10 and K25. Two polymers 
crystallised between day 0 and week 4: VA64 and Soluplus. Three polymers crystallised on day 0: 
K30, KSR and HPMCP. 
The difference in results between acetone/methanol and acetonitrile/methanol is not due to the 
boiling point or enthalpy of vaporisation differences, because evaporation is performed above the 
boiling point and the films are held at this temperature for 2 minutes. There may be a contribution 
from the Kamlet-Taft differences between acetone and methanol. Kamlet-Taft is a separate measure 
of the hydrogen bond donor, hydrogen bond acceptor and polarisability of a solvents as contributors 
to the overall solvent polarity.8 The cyano functional group in acetonitrile and the carbonyl of 
acetone are both polarised. There are also structural differences between the solvents: acetonitrile is 
linear but acetone is planar. Many complex factors are affecting the interaction of these solvent with 
drug and polymers solutes. Considering all relevant factors is beyond the scope of this manuscript, 
but it may be possible to better understand these systems using computational methods. 
Future work may involve longer testing conditions or higher humidity levels. DSC analysis of 
the formulations would add valuable information on the presence of domain structure. 
Formulation/ Solvent Day 0 Wk 4 Formulation/ Solvent Day 0 Wk 4 
Ace-PVP10/ Solv B AAAA AAAA Ace-KSR/ EtOH AAAC ACCC 
Ace-K25/ Solv B AAAA AAAA Ace-HPMCAS/ EtOH ACCC CCCC 
Ace-K30/ Solv B AAAA AAAA Ace-HPMCP/ EtOH ACCC CCCC 
Ace-Sol/ Solv B AAAA ACCC Ace-HPMC/ EtOH CCCC CCCC 
Ace-VA64/ Solv B AAAA AACC Ace-K30/ 
EtOH(80):H2O(20) 
AAAA AAAA 
Ace-KSR/ Solv B AAAC CCCC Ace-K30/ 
EtOH(90):H2O(10) 
AAAA AAAA 
Ace-HPMCAS/ Solv B Not soluble Ace-K30/ EtOH(95):H2O(5) AAAA AAAA 
Ace-HPMCP/ Solv B AAAC CCCC Ace-K30/ 
EtOH(70):H2O(30) 
AAAA AAAA 
Ace-HPMC/ Solv B Not soluble Ace-K30/ 
EtOH(60):H2O(40) 
AAAA AAAA 
Ace-PVP10/ ACN AAAA AAAA Ace-K30/ 
EtOH(50):H2O(50) 
AAAA AAAA 
Ace-K25/ ACN AAAA AAAA Ace-K30/ 
EtOH(40):H2O(60) 
AAAA AAAA 
Ace-K30/ ACN AAAC AAAC Ace-K30/ 
EtOH(20):H2O(80) 
AAAC ACCC 
Ace-Sol/ ACN AAAA AAAC Ace-K30/ 
EtOH(10):H2O(90) 
AAAC CCCC 
Ace-VA64/ ACN AAAA AACC PVP10/Solv A AAAA AAAA 
Ace-KSR/ ACN AAAC CCCC K25/Solv A AAAA AAAA 
Ace-HPMCAS/ ACN Not soluble K30/Solv A AAAA AAAA 
Ace-HPMCP/ ACN AAAC CCCC Sol/Solv A AAAA AAAA 
Ace-PVP10/ EtOH AAAA AAAA VA64/Solv A AAAA AAAA 
Ace-K25/ EtOH AAAA AAAA KSR/Solv A AAAA AAAA 
Ace-K30/ EtOH AAAA AAAA HPMCAS/EtOH-CH3Cl AAAA AAAA 
Ace-Sol/ EtOH AAAA AAAA HPMCP/Solv A AAAA AAAA 
Ace-VA64/ EtOH AAAA AAAA HPMC/EtOH-H2O(1:1) AAAA AAAA 
Table 4, Formulations from 'legacy' solvents: Acetone-methanol (Solv A), acetonitrile-methanol (Solv B), acetonitrile 
(ACN), methanol (MeOH), ethanol (EtOH), chloroform (CH3Cl); Acetaminophen (Ace), Polyvinylpyrrolidone (PVP), 
Kollidon 25 (K25), Kollidon 30 (K30), Soluplus (Sol), Kollidon VA64 (VA64), Kollidon SR (KSR) 
5. CONCLUSIONS 
Miniaturised solvent casting (MSC) is a useful tool in the pre-formulation of drug product 
amorphous solid dispersions. A range of drugs, polymers and solvents are suited to this screening 
technique. A rational ASD selection should take physiochemical properties of drug, polymer and 
solvent into account. The properties of the solvent will affect the stability of the amorphous film 
even after solvent has been removed. 
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